• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Voclosporin shows clinical promise for treatment of active lupus nephritis

byJessie WillisandTeddy Guo
June 9, 2021
in Chronic Disease, Nephrology, Rheumatology
Reading Time: 2 mins read
Multidrug induction therapy increases remission from lupus nephritis
Share on FacebookShare on TwitterShare on LinkedIn

1. A significantly greater proportion of patients in the voclosporin group achieved complete renal responses after 52 weeks compared to the placebo group.

2. The safety profile between the voclosporin group and placebo group were comparable with 21% of patients in both groups experiencing serious adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nearly a quarter of patients with lupus nephritis develop renal failure in ten years. Despite recent clinical trials on promising biologic drugs, an effective oral medication would have additional benefits, such as a lower cost and convenience. Voclosporin is a novel calcineurin inhibitor which holds many pharmacokinetic advantages over its older CNI counterparts, which have long been used to improve renal response rates. This phase III drug trial conducted in 27 countries randomized 357 individuals to either voclosporin or placebo, with both groups receiving standard mycophenolate mofetil and low-dose steroids. After 52 weeks, the voclosporin group had significantly increased rates of complete renal response compared to placebo. The safety profile of both drugs was found to be comparable, with the same percentage of participants experiencing adverse events. A limitation of this study includes its short duration, as this is a preliminary study to be followed for an additional two years. Nonetheless, this phase 3 drug trial provides promising evidence for the efficacy and safety of voclosporin.

Click to read the study in The Lancet

Relevant Reading: Two-year, randomized, controlled trial of Belimumab in lupus nephritis

RELATED REPORTS

Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis

#VisualAbstract: Obinutuzumab Plus Standard Therapy Provided Complete Renal Response in Active Lupus Nephritis

In-Depth [randomized control trial]: This double-blind, randomized phase 3 drug trial recruited 357 patients with active lupus nephritis in 142 clinics across 27 countries between April 13, 2017 to Oct 10, 2019. 179 patients were assigned to receive voclosporin and 178 received a placebo. All patients were given mycophenolate mofetil and low-dose oral steroids. The primary outcome investigated was renal response at week 52 assessed by the independent Clinical Endpoints Committee. Significantly more patients on voclosporin (41%) had a complete renal response compared to placebo (23%; odds ratio 2.65, p<0.0001). This statistical significance in favour of voclosporin was maintained for all secondary outcomes, such as partial response at 52 weeks or complete response at 24 weeks. Safety was determined by occurrence of serious adverse events, which were comparable at 21% of patients in both groups. Analysis was done by intention-to-treat and drop-outs were seen in the voclosporin (9%) and placebo (17%) group.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: kidney failureLupusLupus nephritismycophenolate mofetilnephritisrenal failuresystemic lupus erythematosus (SLE)Voclosporin
Previous Post

Reports of myocarditis in healthy adolescents after Pfizer-BioNTech COVID-19 Vaccination

Next Post

#VisualAbstract: High-dose methylprednisolone vs. dexamethasone for COVID-19 pneumonia

RelatedReports

Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis

May 21, 2025
#VisualAbstract: Obinutuzumab Plus Standard Therapy Provided Complete Renal Response in Active Lupus Nephritis
StudyGraphics

#VisualAbstract: Obinutuzumab Plus Standard Therapy Provided Complete Renal Response in Active Lupus Nephritis

February 21, 2025
Cardiology

Use of hydroxychloroquine may be protective for cardiovascular events in patients with systemic lupus erythematosus 

May 19, 2025
Chronic Disease

Hemodiafiltration reduces mortality compared to hemodialysis in kidney failure with dose-dependent benefits

December 12, 2024
Next Post
#VisualAbstract: Reduced-dose glucocorticoid adjunct non-inferior to high-dose glucocorticoid plus rituximab regimen for induction of disease remission in autoimmune vasculitis

#VisualAbstract: High-dose methylprednisolone vs. dexamethasone for COVID-19 pneumonia

#VisualAbstract: Plasma Epstein-Barr virus DNA may have prognostic value for patients with nasopharyngeal carcinoma

#VisualAbstract: Plasma Epstein-Barr virus DNA may have prognostic value for patients with nasopharyngeal carcinoma

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.